Filing summary
Entity and period: The supplied filing is Immudyne, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2016—not a LifeMD, Inc. filing. Verify the issuer before relying on this summary.
Business context and financial performance
Immudyne develops and sells yeast beta-glucan immune-support products. Its two reported segments are nutraceutical and cosmetic additives and finished cosmetic products. The finished-products business operated through its controlled Puerto Rico subsidiary, Immudyne PR; Immudyne held a 78.16667% ownership and voting interest after an April 2016 agreement amendment.
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Net sales | $1.384 million | $0.280 million | $4.253 million | $0.846 million |
| Gross profit | $442,000 | $206,000 | $1.271 million | $608,000 |
| Gross margin | 32% | 74% | 30% | 72% |
| Operating income (loss) | ($208,000) | $18,000 | ($466,000) | $9,000 |
| Net income (loss) | ($218,000) | $8,000 | ($482,000) | ($11,000) |
| Net income (loss) attributable to Immudyne | ($227,000) | $8,000 | ($489,000) | ($11,000) |
| Operating cash flow | Not stated separately | Not stated separately | ($112,000) | ($80,000) |
Finished cosmetic products generated $1.155 million of Q3 2016 sales and $3.495 million in the first nine months; the comparable 2015 periods had no reported sales in that segment. The filing’s segment note gives 2016 nine-month additives revenue as $780,961, while another note says $757,961; the filing text does not provide a clear reconciled value. Total reported sales are $4,252,704.
Liquidity, debt and capital
- At September 30, 2016, cash was $474,000, current assets $1.079 million, current liabilities $622,000, and working capital $457,000. The current ratio was 1.7 to 1.
- Current notes payable, net of discount, were $214,000. The company reported $150,000 of 11% subordinated notes issued in August and September, due in February and March 2017, plus a $100,000 commercial note due November 1, 2016. The balance-sheet carrying value is net of debt discount.
- Nine-month financing cash flow was $353,000, including $150,000 of increased notes payable, $161,000 invested in the subsidiary by noncontrolling-interest holders, and $46,000 from stock and warrant sales. Cash increased by $241,000.
- Subsequent events: the company reported $18,800 of principal payments in October, repayment of the $100,000 commercial note in November, and an additional $50,000 borrowing under the offering in October, accompanied by 62,500 shares.
Material changes and management commentary
Sales rose 395% in Q3 and 403% for the nine-month period, principally because of the new finished-products segment. Gross margin fell sharply as the sales mix shifted toward lower-margin finished products and marketing costs increased. Management cited approximately $1.71 million of upfront advertising and marketing expense for the finished-products business during the first nine months. Operating expenses increased 246% in Q3 and 190% year to date, including higher compensation, stock-based compensation, and professional fees. Management expects these costs to decrease as a percentage of sales as the subsidiary matures; this is an expectation, not quantified guidance.
Management said sales growth and/or additional capital may be needed to meet 2017 operating and capital requirements. The company had an accumulated deficit of approximately $9.1 million and negative operating cash flow. The filing states these conditions raise substantial doubt about the company’s ability to continue as a going concern. Funding could come from higher sales, equity issuance, debt, or support from officers and directors, but availability is not assured. Potential equity financing would dilute shareholders; borrowing would increase debt service and could impose covenants.
Risks, contingencies and unusual items
- Control weaknesses: Management concluded disclosure controls were ineffective, citing inadequate segregation of duties and risk assessment, insufficient written accounting and reporting procedures, weak computer access/security and disaster-recovery measures, and no written whistleblower policy. Remediation is dependent on sufficient funds.
- Customer concentration: One additives customer represented 15% of nine-month 2016 consolidated sales (83% in the comparable 2015 period). A second represented 2% (13% in 2015). The filing also reports customer discounts, returns, and rebates of approximately $530,000 for Q3 and $1.578 million for the first nine months of 2016.
- Equity compensation and dilution: 2.3 million shares were issued to consultants under service agreements, valued at $690,000; $306,667 was recognized as expense through September. Nine-month stock-based compensation was reported as $513,804 in the notes, while the cash-flow statement reports $493,218, a difference investors may wish to reconcile. Options and warrants were substantial, with 12.95 million potential shares excluded from diluted loss per share as antidilutive.
- Other exposures: The Kentucky facility lease expired in May 2016; operations continued month to month at approximately $9,000 monthly base rent while renewal was discussed. Management reported no known legal matter expected to have a material adverse effect. Certain skin-care royalty obligations had reached their stated cap, though $56,579 remained included in accounts payable and accrued expenses.
Important facts to verify
- Confirm that this Immudyne, Inc. filing is the intended issuer, given the request metadata naming LifeMD, Inc.
- Reconcile the inconsistent nine-month additives revenue figures and the stock-compensation amounts in the notes and cash-flow statement.
- Review the going-concern disclosure, cash needs, and subsequent debt repayments and borrowing against the company’s funding plans.
- Assess whether lower finished-products margins, marketing costs, customer deductions, and customer concentration persist.
- Track remediation of the disclosed material weaknesses and the potential dilution from outstanding options, warrants, and share-based agreements.